ViaCyte Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Employees
-
111
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$320M
ViaCyte General Information
Description
Developer of novel cell replacement therapies and regenerative medicine intended to address critical human diseases and disorders. The company's therapies are based on two major technological advances including cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation, enabling healthcare institutions to reduce the risk of hypoglycemia and diabetes-related complications.
Contact Information
Website
www.viacyte.comCorporate Office
- 5580 Morehouse Drive
- Suite 100
- San Diego, CA 92121
- United States
Corporate Office
- 5580 Morehouse Drive
- Suite 100
- San Diego, CA 92121
- United States
ViaCyte Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 26. Merger/Acquisition | 27-Sep-2022 | $320M | Completed | Clinical Trials - Phase 2 | ||
| 25. Later Stage VC (Series D) | 09-Jun-2021 | Completed | Clinical Trials - Phase 2 | |||
| 24. Secondary Transaction - Private | Completed | Clinical Trials - General | ||||
| 23. Later Stage VC (Series D2) | 26-May-2020 | Completed | Clinical Trials - General | |||
| 22. Later Stage VC | 25-Sep-2018 | Completed | Clinical Trials - General | |||
| 21. Grant | 17-Apr-2018 | Completed | Clinical Trials - General | |||
| 20. Grant | 15-Dec-2017 | Completed | Clinical Trials - General | |||
| 19. Later Stage VC | 22-May-2017 | Completed | Clinical Trials - General | |||
| 18. Grant | 01-Jan-2017 | $23.1M | $104M | Completed | Clinical Trials - General | |
| 17. Grant | 11-Sep-2014 | $16.6M | $104M | Completed | Clinical Trials - General |
ViaCyte Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D-4A | ||||||||
| Series D-4 | ||||||||
| Series D-3A | ||||||||
| Series D-3 | ||||||||
| Series D1 | ||||||||
| Series C1 | ||||||||
| Series C | ||||||||
| Series B | 27,876,992 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 3.89% |
| Series A | 8,020,005 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 1.12% |
ViaCyte Comparisons
Industry
Financing
Details
ViaCyte Competitors (19)
One of ViaCyte’s 19 competitors is Regenerative Medical Solutions, a Venture Capital-Backed company based in Madison, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenerative Medical Solutions | Venture Capital-Backed | Madison, WI | ||||
| Diamyd Medical | Corporation | Stockholm, Sweden | ||||
| BioCardia | Formerly VC-backed | Sunnyvale, CA | ||||
| Sernova Biotherapeutics | Corporation | Mississauga, Canada | ||||
| Orgenesis | Corporation | Germantown, MD |
ViaCyte Patents
ViaCyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250090596-A1 | Modulating inflammation associated with foreign body response | Pending | 14-Sep-2023 | ||
| US-20240249308-A1 | Information processing device, and information processing method | Inactive | 25-Jan-2023 | ||
| EP-4593761-A2 | Anchor regions for implantable medical device | Pending | 30-Sep-2022 | ||
| US-20250269161-A1 | Anchor regions for implantable medical device | Pending | 30-Sep-2022 | ||
| WO-2024073736-A2 | Anchor regions for implantable medical device | Inactive | 30-Sep-2022 | A61F2/022 |
ViaCyte Signals
ViaCyte Former Investors (34)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AMA98 ventures | Limited Partner | Minority | ||
| ARTIS (San Francisco) | Venture Capital | Minority | ||
| ATEL Capital Group | Asset Manager | Minority | ||
| Adage Capital Management | Hedge Fund | Minority | ||
| Alloy Ventures | Venture Capital | Minority |
ViaCyte Acquisitions (1)
ViaCyte’s most recent deal was a Merger/Acquisition with Janssen (BetaLogics). The deal was made on 18-Dec-2015.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Janssen (BetaLogics) | 18-Dec-2015 | Merger/Acquisition | Biotechnology |
ViaCyte FAQs
-
When was ViaCyte founded?
ViaCyte was founded in 1999.
-
Where is ViaCyte headquartered?
ViaCyte is headquartered in San Diego, CA.
-
What is the size of ViaCyte?
ViaCyte has 111 total employees.
-
What industry is ViaCyte in?
ViaCyte’s primary industry is Drug Discovery.
-
Is ViaCyte a private or public company?
ViaCyte is a Private company.
-
What is the current valuation of ViaCyte?
The current valuation of ViaCyte is .
-
What is ViaCyte’s current revenue?
The current revenue for ViaCyte is .
-
How much funding has ViaCyte raised over time?
ViaCyte has raised $276M.
-
Who are ViaCyte’s investors?
AMA98 ventures, ARTIS (San Francisco), ATEL Capital Group, Adage Capital Management, and Alloy Ventures are 5 of 34 investors who have invested in ViaCyte.
-
Who are ViaCyte’s competitors?
Regenerative Medical Solutions, Diamyd Medical, BioCardia, Sernova Biotherapeutics, and Orgenesis are some of the 19 competitors of ViaCyte.
-
When was ViaCyte acquired?
ViaCyte was acquired on 27-Sep-2022.
-
Who acquired ViaCyte?
ViaCyte was acquired by Vertex Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process